Quantitative Urine Protein & Albumin (UPCR/UACR)

KDIGO Standardisation, Unit Conversion & Renal Risk Stratification · v1.0
⚙ Standardisation Protocol: First-morning spot urine is preferred. This tool automatically adjusts diverse laboratory reporting units into standardised KDIGO metrics (mg/g and mg/mmol).

1. Select Target Analysis

2. Laboratory Parameters

⚙ Evidence & Clinical Pearls

⚠ The Concentration Pitfall in Indian Diagnostics:
Many local laboratories report raw "Spot Urine Microalbumin" levels (e.g., 25 mg/L) and flag them as abnormal if they exceed a generic cut-off (usually > 20 mg/L). This is physiologically misleading. A concentrated morning sample will naturally have higher raw solute concentrations. Always divide the raw albumin by urine creatinine (UACR) to normalise for urinary dilution.

KDIGO 2024 Albuminuria Categories (UACR)

Category UACR (mg/g) Clinical Interpretation
A1 < 30 Normal to mildly increased. Minimal risk if eGFR is preserved.
A2 30 – 300 Moderately increased (formerly microalbuminuria). Indicates early endothelial dysfunction or early Diabetic Kidney Disease.
A3 > 300 Severely increased (formerly macroalbuminuria). High risk for progression to ESRD and cardiovascular events.

Total Proteinuria Categories (UPCR)

While UACR is more sensitive for early diabetic or hypertensive changes, UPCR is essential for evaluating broader glomerular diseases where non-albumin proteins (e.g., globulins, light chains) are excreted.

  • Normal: < 150 mg/g (< 0.15 mg/mg)
  • Mild / Sub-nephrotic: 150 to 500 mg/g
  • Moderate / Overt: 500 to 3500 mg/g
  • Nephrotic Range: > 3500 mg/g (> 3.5 mg/mg). Requires prompt nephrology referral for probable biopsy.

Illness Scripts: Top 3 Aetiologies

Diagnosis Typical Ratio Profile Key Clinical Features
Diabetic Kidney Disease (DKD) Predominant UACR elevation initially (A2 → A3). Bland urinary sediment. Retinopathy often co-exists. Gradual progression.
Glomerulonephritis (e.g., IgA) High UPCR. Often nephrotic range. Active sediment (dysmorphic RBCs, RBC casts). Acute onset or post-infectious.
Hypertensive Nephrosclerosis Mild UACR/UPCR elevation (< 1000 mg/g). Long-standing HTN, LVH on ECG, small/contracted kidneys on ultrasound.
Therapeutic Implications: The presence of A2 or A3 albuminuria provides a compelling indication to initiate nephroprotective agents independent of glycaemic control. First-line agents include ACE inhibitors or ARBs (titrated to maximum tolerated dose) and SGLT2 inhibitors (e.g., Dapagliflozin, Empagliflozin). Non-steroidal MRAs (Finerenone) are indicated for residual albuminuria in Type 2 DM.
Abbreviations: UACR (Urine Albumin-to-Creatinine Ratio) · UPCR (Urine Protein-to-Creatinine Ratio) · KDIGO (Kidney Disease: Improving Global Outcomes) · eGFR (Estimated Glomerular Filtration Rate) · ESRD (End-Stage Renal Disease)
Algorithm References & Evidence Base
  1. Kidney Disease: Improving Global Outcomes (KDIGO) 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314.
  2. Association of Physicians of India (API). API Guidelines on Management of Chronic Kidney Disease. In: API Medicine Update. 2023.
  3. Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults. JAMA. 2015;313(8):837-846.
How to Cite This Tool

AMA Style:
Umakanth S. Quantitative Urine Protein & Albumin (UPCR/UACR) Calculator. MEDiscuss. Published 2026. Accessed .

Vancouver Style:
Umakanth S. Quantitative Urine Protein & Albumin (UPCR/UACR) Calculator [Internet]. MEDiscuss.org; 2026 [cited ]. Available from:

⚠ Disclaimer: This decision-support system is intended for healthcare professionals. It does not substitute clinical judgment. These algorithms are evidence-based, but medical knowledge evolves continuously. The treating physician retains absolute responsibility for all diagnostic, dosing, and therapeutic decisions. Always verify outputs against current institutional protocols and individual patient contexts.
© 2026 MEDiscuss.org. All rights reserved. This CDSS Module was designed and developed by
Dr. Shashikiran Umakanth using the available evidence base. Provided free of charge for clinical use. Unauthorised reproduction or redistribution is strictly prohibited.
Category Foundational Calculators
Specialties Nephrology
Status New Pathway
Related Clinical Tools
Renal Staging PathwayInpatient Antimicrobial DosingNACO First-Line ART Initiation Pathway
Back to All Medical Calculators & Pathways